Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Syndax Pharmaceuticals Inc to Host an Investor Call Transcript

Oct 02, 2023 / 12:00PM GMT
Release Date Price: $13.5 (-7.02%)
Operator

Good day, everyone, and welcome to the Pivotal AUGMENT-101 top line Revumenib data conference call. Today's call is being recorded. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.

Sharon Klahre
Syndax Pharmaceuticals, Inc. - VP of IR & Communications

Thank you, operator. Welcome, and thank you all for joining us today. I'm Sharon Klahre and with me this morning to provide a review of topline results from the Pivotal AUGMENT-101 trial of Revumenib in relapsed/refractory adult and pediatric patients with KMT2Ar, acute leukemia, are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D. Also joining us on the call today for question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; Dr. Anjali Ganguli, Chief Business Officer; and Keith Goldan, Chief Financial Officer.

This morning, we issued a press release and reported topline data for the Pivotal AUGMENT-101 trial of Revumenib in relapsed or refractory KMT2Ar acute

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot